Please assess the completion status of the following clinical trial:

Trial Title: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 40 to ≤ 85 years of age~* History of clinically evident cardiovascular disease at high risk for a recurrent event~* Fasting low-density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL (≥ 1.8 mmol/L) ) or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL (\> 2.6 mmol/L)~* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)~Exclusion Criteria:~* New York Heart Association (NYHA) class III or IV, or last known left ventricular ejection fraction \< 30%~* Uncontrolled hypertension~* Uncontrolled or recurrent ventricular tachycardia~* Untreated hyperthyroidism or hypothyroidism~* Homozygous familial hypercholesterolemia~* LDL or plasma apheresis

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.
- Evolocumab (Type: EXPERIMENTAL): Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference.

Based on this trial design, predict the completion outcome and termination type (if applicable).